International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(14), С. 7711 - 7711

Опубликована: Июль 14, 2024

Sodium–glucose cotransporter 2 inhibitors (SGLT2i), a novel class of glucose-lowering drugs, have revolutionized the management heart failure with reduced and preserved ejection fraction, regardless presence diabetes, are currently incorporated in guidelines. While these drugs consistently demonstrated their ability to decrease hospitalizations several landmark clinical trials, cardioprotective effects far from having been completely elucidated. In past decade, growing body experimental research has sought address molecular cellular mechanisms SGLT2i order provide better understanding off-target acute chronic cardiac benefits, beyond on-target renal effect responsible for blood glucose reduction. The present narrative review addresses direct SGLT2i, delving into approved therapy, provides insights future perspectives.

Язык: Английский